Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells
Treatment of Premature Ovarian Insufficiency Using Autologous Bone Marrow Concentrates Through Transvaginal Approach Under Ultrasound Guidance
abdulmajeed hammadi
10 participants
Mar 1, 2024
INTERVENTIONAL
Conditions
Summary
investigator is doing single armed clinical interventional study to treat premature ovarian insufficiency with autologous bone marrow derived mononuclear cells to be given systematically and locally to the ovaries under ultrasound guidance with experienced gynecologist and to look for the results including: laboratory evidence through hormonal study ultrasound proof of ovarian follicle development. premature ovarian insufficiency is characterized by early loss of ovarian function (less than 40 years of age) manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotropin hormones and low estrogen and anti-Mullerian hormone. Autologous use of stem cells from bone marrow are alternative safe minimal manipulative products that can provide a solution to this clinical problem without the need for oocyte donation program.
Eligibility
Inclusion Criteria3
- clinical diagnosis of premature Ovarian insufficiency.
- ineffective hormonal therapy.
- biochemical evidence of high gonadotropins.
Exclusion Criteria3
- solid or hematological malignancies.
- bleeding disorders.
- rejection of the procedure.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
under general anesthesia bone marrow aspiration done followed by cell concentration and transvaginal ovarian injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06302543